News

In total, the company has already received Orphan drug designation for vaccines for pancreatic cancer, acute myeloid leukemia and chronic myeloid leukemia. BioSante Pharma president and CEO Stephen

ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of all forms of ATTR, which includes FAP and familial amyloidotic cardiomyopathy (FAC). Alnylam Regulatory Affairs

The new tools and systems are anticipated to allow NuVax to develop three separate cancer therapeutics for the treatment of Multi Myeloma, Pancreatic Cancer and Lung Cancer. As

Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this

The company has posted a net income of $5.63m for the fourth quarter 2010, or $0.14 per diluted share, compared to $5.81m, or $0.15 per diluted share, for

CBLB502 is said to a bioengineered derivative of a microbial protein that helps in reducing injury from acute stresses, such as radiation and chemotherapy. Cleveland BioLabs Public Health

Under a contract with the Henry M Jackson Foundation for the Advancement of Military Medicine, GenVec will receive funding for the development and preparation of vaccines related to

The randomised, double blind and placebo-controlled study will enroll up to 300 patients, and will be conducted at 40 sites across the US. In the study, Serdaxin will

The company will launch the allergy drug in the US as an OTC in March 2011. Sanofi-aventis Global Operations president Hanspeter Spek said leveraging their US Consumer Healthcare